Literature DB >> 1833074

The coexpression of CD45RA and CD45RO isoforms on T cells during the S/G2/M stages of cell cycle.

J M LaSalle1, D A Hafler.   

Abstract

The tyrosine phosphatase CD45 is alternatively spliced to generate isoforms of different molecular weights (180-220 kDa) which are differentially expressed on hematopoietic cells. Monoclonal antibodies reacting with either the 180-kDa (UCHL-1, CD45RO) or the 200- to 220-kDa (2H4, CD45RA) isoform have been used to subdivide T cell populations based on their expression of one or the other of these two epitopes. CD45RA T cells have "naive" characteristics of unresponsiveness to recall antigens and prominence in cord blood, while CD45RO T cells are considered "memory" T cells because they proliferate to recall antigens and increase following PHA activation of cord blood. However, we have recently demonstrated the expression of the CD45RA isoform on a subpopulation of CD45RO+ T cell clones, suggesting that CD45RA is not a universal marker for naive T cells. Using propidium iodide staining of the DNA to determine cell cycle stage, we now show that CD45RA expression is significantly higher on T cell clones during the S, G2, and M stages of cell cycle when compared to CD45RA expression on cells in Go and G1. Furthermore, CD45RA expression on cells undergoing mitosis is not limited to long-term activated T cell clones, as uncultured peripheral blood T cells in the S/G2/M phase express significantly more CD45RA. The percentage of T cells coexpressing CD45RA and CD45RO also increases following PHA activation, indicating that T cells in the process of division express both isoforms. These results suggest a potential role of the CD45RA isoform during the stages of cell cycle leading to mitosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833074     DOI: 10.1016/0008-8749(91)90144-z

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  12 in total

1.  Ex vivo expansion and Th1/Tc1 maturation of umbilical cord blood T cells by CD3/CD28 costimulation.

Authors:  Melissa A Mazur; Craig C Davis; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

2.  Identical expression of CD45R isoforms by CD45RC+ 'revertant' memory and CD45RC+ naive CD4 T cells.

Authors:  M Hargreaves; E B Bell
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

3.  Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1.

Authors:  S Imlach; S McBreen; T Shirafuji; C Leen; J E Bell; P Simmonds
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells.

Authors:  Y B Sullivan; A L Landay; J A Zack; S G Kitchen; L Al-Harthi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

5.  Dual expression of CD45RA and CD45RO isoforms on myelin basic protein-specific CD4+ T-cell lines in multiple sclerosis.

Authors:  Y Qin; S Van Den Noort; J Kurt; S Gupta
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

6.  Co-expression of the CD45RA and CD45RO antigens on T lymphocytes in chronic arthritis.

Authors:  K L Summers; J L O'Donnell; D N Hart
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

7.  Protein kinase C isoform expression in CD45RA+ and CD45RO+ T lymphocytes.

Authors:  E Corrigan; D Kelleher; C Feighery; A Long
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

8.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Authors:  J W Gratama; R J Bruin; C H Lamers; R Oosterom; E Braakman; G Stoter; R L Bolhuis
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  IL-6 enhances CD4 cell motility by sustaining mitochondrial Ca2+ through the noncanonical STAT3 pathway.

Authors:  Felipe Valença-Pereira; Qian Fang; Isabelle J Marié; Emily L Giddings; Karen A Fortner; Rui Yang; Alejandro V Villarino; Yina H Huang; David A Frank; Haitao Wen; David E Levy; Mercedes Rincon
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 12.779

10.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  J Zhang; S Markovic-Plese; B Lacet; J Raus; H L Weiner; D A Hafler
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.